<DOC>
	<DOC>NCT03052296</DOC>
	<brief_summary>The purpose of the BIOLUX P-III Spain registry is to further investigate the safety and clinical performance of the Passeo-18 Lux Drug Coated Balloon in the treatment of long atherosclerotic femoropoliteal artery lesions in daily clinical practice</brief_summary>
	<brief_title>BIOLUX P-III SPAIN All-Comers Registry</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Age ≥ 18 years or minimum age as required by local regulations Subject must be willing to sign a Patient Data Release Form (PDRF) or Patient Informed Consent (PIC) where applicable Subject classified as Rutherford class 4, 5 or 6 TASC C or D lesion(s) in the femoropopliteal artery Lesion length &gt; 15 cm suitable for endovascular treatment treated with or scheduled to be treated with the Passeo18 Lux drug releasing balloon Life expectancy ≤ 1 year Subject is currently participating in another investigational drug or device study that has not reached its primary endpoint yet. Subject is pregnant or planning to become pregnant during the course of the study. Rutherford class &lt;4 Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations). Intraprocedural decision not to proceed with the Passeo18 Lux DCB for any reason not related to the device (for instance blood flow limiting dissection after predilatation).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>